$ISRG

Jeddi Iman sold $2.4M of ISRG

Jeddi Iman (SVP & GM da Vinci Platforms &) sold 5,625 shares of INTUITIVE SURGICAL INC (ISRG) at $420.55 ($2.37M total) on 2026-06-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Jeddi Iman
Published Jun 2, 2026, 2:08 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 2, 2026, 2:10 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$ISRG
Neutral
medium confidence
Mentioned
$ISRG
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ISRGNeutralLow
01

Why it matters

Because the sale is pre-arranged, it is generally treated as lower-signal for company-specific negative news; the main tradable element is short-term sentiment/positioning.

02

Market read

A disclosed insider sale in ISRG, but with 10b5-1 framing, suggesting limited fundamental implications.

03

What to watch

Check whether this sale is part of a larger sequence of officer sales or whether other insiders are buying/selling around the same window.

Relevance 6/10Novelty 6/10Timing: Filed June 2; sale executed June 1

Background

The filing is an SEC Form 4 for an officer (SVP & GM da Vinci Platforms) reporting an open-market sale executed under a pre-arranged Rule 10b5-1 plan.

Company-level read

Ticker impact

$ISRGNeutralMedium confidence
Context

Intuitive Surgical disclosed an officer open-market sale of 5,625 shares under a pre-arranged 10b5-1 plan on June 1.

Expected impact

Low likelihood of sustained price impact; any reaction is likely brief unless follow-on selling accelerates.

Evidence & confidence

The transaction is explicitly under a pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary sales.

Market effects

Minimal; single-company 10b5-1 sale does not reset sector expectations.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can still coincide with internal caution about near-term execution or valuation.

Key entities

  • Intuitive Surgical

    Subject of the Form 4 insider transaction disclosure.

  • Jeddi Iman

    Officer reporting the sale of ISRG shares.

  • Rule 10b5-1 plan

    Pre-arranged trading plan that reduces discretionary interpretation.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$ISRGHighAI 8/10

Intuitive receives CE mark for transvaginal use of da Vinci SP system

Intuitive Surgical (ISRG) received CE mark approval for its da Vinci SP system for transvaginal gynecological procedures in Europe, expanding its use in women's health. The system, already approved for other surgeries, allows single-incision operations, potentially improving recovery and outcomes. It is also approved in the US, Japan, and Korea.

$ISRGHigh

Intuitive announces expanded indication for da Vinci SP in Europe

Intuitive (ISRG) received CE mark approval for transvaginal gynecologic procedures using the da Vinci SP system in Europe, expanding its applications. The approval allows for less invasive options and potentially better recovery experiences. The system is already approved in the US, Japan, and Korea for various procedures.

$IARTMedAI 8/10

Q2 Earnings Outperformers: Integra LifeSciences (NASDAQ:IART) And The Rest Of The Surgical Equipment & Consumables - Specialty Stocks

Integra LifeSciences (IART) reported flat Q2 revenue of $418.8M, meeting expectations. Teleflex (TFX) saw 28.9% revenue growth, beating estimates. LeMaitre (LMAT) missed expectations with 9.6% growth. Intuitive Surgical (ISRG) reported 18.5% growth, beating estimates. All stocks declined post-earnings, with IART down 17.7%, TFX flat, LMAT down 24.9%, and ISRG down 12.3%.

$ISRGMed

ISRG Stock Trading at its Cheapest in 10 Years: Should You Buy Now?

Intuitive Surgical (ISRG) trades at its lowest valuation in a decade, with a forward P/E of 30.26x, below its 10-year median. Despite a 40% decline, Q2 2026 revenue grew 19% to $2.89B, and EPS rose 28%. Management maintained 2026 da Vinci procedure growth forecast at 13.5-15.5%, citing international growth but noting U.S. and China uncertainties. ISRG's product pipeline includes da Vinci 5 and Ion systems, with innovations like SP procedures up 61%. Shares lag industry and sector, down 15% in 3